PTA-News: Medigene AG: Change in the Executive Management Board

Thursday, 18. March 2021 22:30

Business news for the stock market

Planegg/Martinsried (pta044/18.03.2021/22:30) - 18 March 2021. Dr. Kai Pinkernell, Chief Medical Officer and Chief Development Officer (CMO&CDO) of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, will leave the Company's Executive Management Board for personal reasons as of 31 March 2021. Dr. René Goedkoop will assume the role of acting CMO and will be responsible for the continuation of Medigene's clinical projects, primarily driving the finalization of the Phase I part of the ongoing clinical trial with MDG1011 in patients with acute myeloid leukemia or myelodysplastic syndrome. Dr. Goedkoop previously has held several CMO positions in international biopharmaceutical companies such as Sensimed S.A., Lausanne, Switzerland, EryDel S.p.A., Bresso (Milan), Italy, or Pharnext S.A., Paris, France, and has had a lead role already in Medigene's clinical trials as Vice President Clinical Affairs since January 2019. Dr. Pinkernell will continue to support Medigene in an advisory role for six months.

Dr. Gerd Zettlmeissl, Chairman of Medigene's Supervisory Board: "Kai served Medigene as Senior Vice President and CMO since February 2016 and became a Member of the Executive Management Board in April 2018. On behalf of the Supervisory Board, I would like to thank Kai for his significant contributions to Medigene."

Prof. Dolores Schendel, Chief Executive Officer and Chief Scientific Officer at Medigene, added: "Kai was a valued member of the Executive Management Board and during this time mainly drove our clinical trials and advanced the cell therapy manufacturing processes. We wish him all the best in his future endeavors. At the same time, we are pleased that René is stepping up as acting CMO and assumes responsibility for the ongoing clinical studies, ensuring their smooth continuation. With his broad experience he will also contribute to the successful strategic refocus towards solid tumor indications."

--- end of press release ---

About Medigene
Medigene AG (FSE: MDG1, Prime Standard, ISIN DE000A1X3W00) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Medigene
Dr. Gary Waanders, Dr. Anna Niedl
Phone: +49 89 2000 3333 01
e-mail: investor@medigene.com
LifeSci Advisors
Mary-Ann Chang
Phone: +44 7483 284 853
e-mail: mchang@lifesciadvisors.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)

emitter: Medigene AG
address: Lochhamer Straße 11, 82152 Planegg/Martinsried
country: Germany
contact person: Medigene PR/IR
phone: +49 89 2000 3333 01
e-mail: investor@medigene.com
website: www.medigene.com

ISIN(s): DE000A1X3W00 (share)
stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate

[ source: http://www.pressetext.com/news/20210318044 ]

Related Links: Medigene AG
Author: